Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

NCT02971683 PHASE3 COMPLETED Results posted

Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Details

Lead sponsor	Bristol-Myers Squibb
Phase	PHASE3
Status	COMPLETED
Enrolment	149
Start date	Thu May 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Polymyositis
• Dermatomyositis
• Autoimmune Necrotizing Myopathy
• Overlap Myositis
• Juvenile Myositis Above the Age of 18

Interventions

• Abatacept subcutaneous
• Placebo

Countries

France, Italy, Japan, Sweden, Germany, Mexico, South Korea, Australia, United States, Brazil, Czechia